Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial to investigate ivosidenib or enasidenib in combination with standard induction (7+3 ) and consolidation chemotherapy followed by a maintenance therapy period in newly diagnosed acute myeloid leukaemia patients with an IDH mutation

Trial Profile

A phase III trial to investigate ivosidenib or enasidenib in combination with standard induction (7+3 ) and consolidation chemotherapy followed by a maintenance therapy period in newly diagnosed acute myeloid leukaemia patients with an IDH mutation

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Enasidenib (Primary) ; Ivosidenib (Primary) ; Antineoplastics; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms HOVON-150
  • Most Recent Events

    • 01 Nov 2018 According to an Agios Pharmaceuticals media release, this trial is expected to begin by the year end 2018.
    • 08 Jan 2018 According to an Agios Pharmaceuticals media release, this trial is expected to begin in the fourth quarter of 2018.
    • 18 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top